CONMED Corp. 10-Q Summary: Quarter Ended September 30, 1999
Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 1999, for CONMED Corporation, a developer and manufacturer of medical instruments and systems for surgical and other medical procedures. The company operates in various clinical settings including operating rooms and hospitals. The financial statements are unaudited.
Key Financial Metrics
| Metric (in thousands) | Q3 1999 | Q3 1998 | 9M 1999 | 9M 1998 |
|---|---|---|---|---|
| Net Sales | $91,712 | $85,714 | $273,064 | $246,469 |
| Cost of Sales | $45,036 | $41,121 | $131,403 | $126,377 |
| Gross Margin % (Adj.) | 52.7% | 52.0% | 52.5% | 49.9% |
| Operating Income | $16,982 | $17,060 | $53,053 | $43,175 |
| Net Income | $5,613 | $5,921 | $18,625 | $11,350 |
| Diluted EPS | $0.36 | $0.39 | $1.19 | $0.74 |
| Cash from Operations (9M) | $19,464 | $14,039 | ||
| Total Debt (Long-term + Current) | $405,504 (Sep 1999) | |||
| Cash & Equivalents | $2,817 (Sep 1999) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.0% in Q3 and 10.8% for the nine months ended September 1999 compared to the prior year. Growth was driven by increased volumes in orthopaedic products and the inclusion of acquired businesses (3M Arthroscopy and Powered Instrument lines).
- Profitability: While Q3 operating income was slightly lower than the prior year ($16.98M vs $17.06M), nine-month operating income rose significantly to $53.05M from $43.18M. Net income for the nine months increased 64% to $18.6M, aided by the absence of an extraordinary charge present in the prior year.
- Acquisition Impact: The August 1999 acquisition of 3M's powered surgical instrument business added $1.6M to cost of sales due to purchase accounting adjustments (inventory step-up). Excluding this, gross margins improved due to higher-margin orthopaedic sales and direct distribution pricing.
- Debt and Interest: Interest expense increased to $8.2M in Q3 (from $7.8M) and $24.0M for nine months (from $23.0M) due to new term loans funding the 3M acquisition.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash from operations and available credit ($65M remaining on a $100M revolver) are sufficient for working capital and debt service. Net working capital increased to $105.5M.
- Capital Structure: The company holds $130M in subordinated notes (9.0% interest, due 2008) and term loans totaling $239.6M. Interest rate swaps are in place to fix rates on $100M of floating debt.
- Year 2000 (Y2K): The company states all systems are remediated and costs were not material, though risks remain regarding third-party failures.
- Foreign Operations: Risks include currency devaluation and the Euro conversion, though management does not anticipate material financial impact.
- Forward-Looking Statements: Results are subject to risks including competition, technology changes, and integration of acquisitions.
Investor Verification Checklist
- Verify the sustainability of gross margin improvements (52.5% for 9M) once acquisition-related inventory step-up adjustments are fully realized.
- Monitor debt service coverage given the increase in interest expense and total debt load exceeding $400M.
- Confirm the integration progress and revenue contribution of the 3M Powered Instrument and Arthroscopy acquisitions.
- Review the impact of the shift from Zimmer distribution to direct sales on future pricing and selling expenses.
- Assess the company's ability to maintain credit facility covenants, specifically working capital levels and financial ratios.